An Investigational Medication From GSK Has The Potential To Lessen Severe Asthma Episodes
In a late-stage trial, GSK’s experimental medicine achieved its main objective of lowering asthma episodes, providing hope for a therapy that the British pharmaceutical anticipates would reach peak annual sales of 3 billion pounds ($3.81 billion). According to GSK, the medication known as depemokimab shown “significant and meaningful reductions” in the frequency of asthma episodes…









